notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2023 included $
1.3
billion of notes due in 2024 and $
69
million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was
5.18
% and
5.14
% for the years ended December 31, 2024 and 2023, respectively. There were no commercial paper borrowings outstanding at December 31, 2024 or 2023.
Long-Term Debt
Long-term debt at December 31 consisted of:
Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of
5.02
% and
4.82
% for 2024 and 2023, respectively.
With the exception of the
6.30
% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme LLC. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company
104
Table of Content
s
(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
In May 2024, MSD Netherlands Capital B.V., a wholly owned finance subsidiary of Merck, completed a registered public offering of €
3.4
billion in aggregate principal amount of euro-dominated senior notes comprised of €
850
million of
3.25
% senior notes due 2032, €
850
million of
3.50
% senior notes due 2037, €
850
million of
3.70
% senior notes due 2044 and €
850
million of
3.75
% senior notes due 2054 (collectively, the Euronotes). The Company has fully and unconditionally guaranteed all of MSD Netherlands Capital B.V.’s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. MSD Netherlands Capital B.V. is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of MSD Netherlands Capital B.V. are consolidated in the financial statements of the Company. The net cash proceeds from the offering were used for general corporate purposes.
Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.
The aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $
2.6
billion; 2026, $
2.2
billion; 2027, $
1.5
billion; 2028, $
2.1
billion; 2029, $
1.7
billion. Interest payments related to these debt obligations are as follows: 2025, $
1.2
billion; 2026, $
1.2
billion; 2027, $
1.1
billion; 2028, $
1.1
billion; 2029, $
1.0
billion.
The Company has a $
6.0